Ajovy Availability: A Provider Briefing for 2026

For neurologists, headache specialists, and primary care providers who prescribe Ajovy (Fremanezumab-vfrm), patient access challenges have become a recurring conversation in clinical practice. While Ajovy remains an effective and well-tolerated option for migraine prevention, the realities of specialty pharmacy distribution, payer requirements, and cost barriers can complicate treatment plans.

This briefing covers the current availability landscape, prescribing considerations, and practical tools to help your patients maintain access to Ajovy in 2026.

Current Supply Status

As of early 2026, Ajovy is not listed on the FDA's or ASHP's drug shortage databases. Teva Pharmaceuticals has not reported any manufacturing or supply disruptions affecting the U.S. market.

However, providers should be aware that patient-reported access difficulties persist, driven primarily by:

• Specialty pharmacy distribution requirements — prescriptions sent to retail pharmacies are frequently rejected or reported as "out of stock"
• Insurance prior authorization and step therapy — particularly with UnitedHealthcare, CVS Caremark, and state Medicaid programs
• Cost barriers for uninsured and underinsured patients — with cash prices exceeding $690 per monthly dose

The distinction between a supply shortage and an access barrier is important: most Ajovy availability issues are distribution and payer-related, not manufacturing-related.

Timeline: Ajovy Availability History

A brief timeline for context:

• September 2018: FDA approval for preventive treatment of migraine in adults
• February 2020: FDA approval of the prefilled autoinjector pen formulation
• 2024: Reports of intermittent supply disruptions at some specialty pharmacies, attributed to increased demand across the CGRP inhibitor class
• 2025: Expanded FDA approval for adolescents aged 12+ weighing ≥45 kg
• Early 2026: No active FDA/ASHP shortage listing; availability generally stable through specialty channels

Prescribing Implications

When prescribing Ajovy, consider the following to minimize patient access issues:

Route the Prescription Correctly

Ajovy should be prescribed to a specialty pharmacy, not a standard retail pharmacy. Common specialty pharmacy partners include CVS Specialty, Accredo (Express Scripts), Optum Specialty, and AllianceRx Walgreens Pharmacy. Sending prescriptions to the patient's insurance-preferred specialty pharmacy can significantly reduce fulfillment delays.

Anticipate Prior Authorization

Most commercial and government payers require prior authorization for Ajovy. Common requirements include:

• Documented diagnosis of episodic or chronic migraine
• Failure, contraindication, or intolerance to at least two preventive therapies (e.g., topiramate, propranolol, amitriptyline, venlafaxine)
• Documentation of migraine frequency (typically ≥4 migraine days per month for episodic, ≥15 headache days per month for chronic)

Electronic prior authorization is available through CoverMyMeds (covermymeds.com or 1-866-452-5017), which can expedite the process.

Dosing Flexibility

Ajovy offers two dosing regimens, both FDA-approved:

• 225 mg subcutaneous injection monthly
• 675 mg (3 × 225 mg) subcutaneous injection quarterly

The quarterly option may be advantageous for patients with adherence concerns or those who prefer fewer injections. Both regimens have demonstrated comparable efficacy in clinical trials.

Cost and Access Landscape

Understanding the cost picture helps providers guide patients through financial barriers:

• Cash price: $690–$1,019 per 225 mg injection (monthly dose)
• Ajovy Savings Card: Commercially insured patients may pay as little as $0–$15/dose (not available for government insurance)
• Teva Cares Foundation: Patient assistance program providing Ajovy at no cost to eligible uninsured/underinsured patients (tevacares.org, 1-877-237-4881)
• Teva Shared Solutions: Comprehensive patient support including pharmacy coordination and insurance navigation (1-800-887-8100)

For patients on Medicare, Medicaid, or other government programs, the manufacturer savings card is not applicable, and coverage varies significantly by plan and state.

Alternative CGRP Therapies

When Ajovy access is compromised, several alternative CGRP-targeted therapies may be appropriate:

• Aimovig (Erenumab): CGRP receptor antagonist, 70–140 mg monthly SC injection (Amgen/Novartis)
• Emgality (Galcanezumab): CGRP ligand inhibitor, 120 mg monthly SC injection after 240 mg loading dose (Eli Lilly). Also indicated for episodic cluster headache.
• Vyepti (Eptinezumab): CGRP ligand inhibitor, 100–300 mg IV infusion quarterly (Lundbeck). May be preferred for patients who need clinic-administered dosing.
• Qulipta (Atogepant): Oral CGRP receptor antagonist, 10–60 mg daily tablet (AbbVie). Preferred by patients who want to avoid injections.

Switching between CGRP inhibitors is generally well-tolerated and can be done at the time the next dose would be due. Detailed alternative comparisons are available in our patient-facing guide: Alternatives to Ajovy.

Tools and Resources for Providers

The following resources can help streamline Ajovy prescribing and patient access:

• Medfinder for Providers: Check real-time pharmacy availability for Ajovy and other specialty medications
• CoverMyMeds: Electronic prior authorization (covermymeds.com)
• Teva Shared Solutions: 1-800-887-8100 — patient support for pharmacy coordination, insurance navigation, and financial assistance
• Ajovy HCP Portal: ajovyhcp.com — prescribing information, support resources, and savings program enrollment

Looking Ahead

Several trends may affect Ajovy prescribing and access in the coming year:

• No biosimilar timeline: No biosimilar or generic Fremanezumab is currently in development or expected in the near term, meaning Teva remains the sole manufacturer.
• Expanding CGRP class: As oral CGRP options like Qulipta gain market share, some payers may shift formulary preferences, potentially affecting step therapy requirements for injectable CGRP inhibitors.
• Payer policy evolution: Some commercial plans have begun reducing step therapy requirements for CGRP inhibitors as real-world evidence accumulates, though this varies widely by plan.

Final Thoughts

Ajovy remains a valuable tool for migraine prevention with a favorable safety profile and flexible dosing options. The primary barriers to patient access in 2026 are distribution logistics and payer requirements — not supply availability.

By routing prescriptions to appropriate specialty pharmacies, proactively managing prior authorization, and connecting patients with financial assistance programs, providers can help ensure their patients maintain consistent access to effective migraine prevention.

Visit Medfinder for Providers to check real-time availability and streamline your patients' access to Ajovy.